FDA warns Hello Cake, an online telehealth seller, that its website misbrands compounded sildenafil and tadalafil ED drugs as equivalent to Viagra and Cialis.
What happened
FDA reviewed the website hellocake.com in August 2025 and found it offering compounded drug products containing sildenafil and tadalafil. The site stated that its "Cake Meds" have "the exact same active ingredients as the branded variety" and called the ingredients "Viagra" and "Cialis." Because compounded drugs are not FDA-approved, FDA says these claims falsely suggest the products are the same as approved drugs, which makes them misbranded.
What FDA found
Website statements saying the products have the exact same active ingredients as the brand-name pill imply they are the same as an FDA-approved drug, which is false or misleading labeling.
Section 502(a) of the FDCA [21 U.S.C. § 352(a)]Advertising or promotion of a compounded drug that is false or misleading misbrands that drug.
Section 502(bb) of the FDCA [21 U.S.C. § 352(bb)]Sending misbranded drugs across state lines is a prohibited act.
Section 301(a) of the FDCA [21 U.S.C. § 331(a)]Receiving misbranded drugs in interstate commerce, or delivering them, is also prohibited.
Section 301(c) of the FDCA [21 U.S.C. § 331(c)]The compounded sildenafil and tadalafil products are "new drugs" because they are not generally recognized as safe and effective for their labeled uses.
Section 201(p) of the FDCA [21 U.S.C. § 321(p)]
What FDA wants
FDA tells the company to take immediate action, including stopping use of the cited language, and to send a written response to CDER's Office of Compounding Quality and Compliance within 15 working days describing the steps taken and how recurrence will be prevented, with supporting documents.
Who should pay attention
- telehealth and online pharmacy operators selling compounded prescription drugs
- compounding pharmacies that supply or white-label products for online brands
- regulatory and marketing reviewers of prescription drug websites
This is a summary. Read the original letter on fda.gov.